HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Warning Letter Depicts Personal-Care Regulation's Present, Possible Future

This article was originally published in The Rose Sheet

Executive Summary

Cosmetic firms already are being closely watched by FDA for overreaching product claims, but if formal good manufacturing practices are established for the sector down the road under regulatory reform legislation, companies could be targeted increasingly with warning letters like that issued to Beauty & Health International for quality-control violations at its Garden Grove, California facility.

You may also be interested in...



Think FDA Inspections Are Painful Now? These Could Be The Good Old Days

ICMAD's recent regulatory workshop offered perspective from FDA's Linda Katz and industry experts on the inspection process for cosmetics facilities under current law. It's clear that FDA inspections can be an ordeal, but that would pale in comparison to challenges that could arise under the proposed Personal Care Products Safety Act.

Aloe Farms' Claims, GMP Practices Rub FDA The Wrong Way

The firm's violative label claims include Aloe Vera Gel "cures everything" and its branding mistakes include failing to list all ingredients for its Aloe Capsules and Original Whole Leaf Aloe Vera Capsules.

CIR Panel Emphasizes GMPs In Final 'Safe As Used' Ingredient Reports

Hexamethylene diisocyanate polymers and keratin/keratin-derived ingredients are safe as currently used in the cosmetics sector, provided that good manufacturing practices are being employed, the Cosmetic Ingredient Review Expert Panel suggests. The group issued four final assessments, advanced a slew of tentative reports and finalized its 2017 review priorities at its June 6-7 meeting in Washington.

Related Content

Topics

UsernamePublicRestriction

Register

RS019936

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel